Want to see ALMS full AI Analyst Report?
ALMS Stock Chart & Stats
$23.03
-$0.30(-1.06%)
At close: 4:00 PM EDT
$23.03
-$0.30(-1.06%)
Day’s Range― - ―
52-Week Range$4.28 - $31.35
Previous CloseN/A
Volume1.16M
Average Volume (3M)3.96M
Market Cap
$903.76M
Enterprise Value$3.13B
Total Cash (Recent Filing)$502.29M
Total Debt (Recent Filing)$36.43M
Price to Earnings (P/E)―
Beta-1.39
Next Earnings
Nov 12, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.80
Shares Outstanding129,435,240
10 Day Avg. Volume2,221,244
30 Day Avg. Volume3,964,984
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)27.54
Price to Sales (P/S)345.07
P/FCF Ratio-22.42
Enterprise Value/Market Cap3.46
Enterprise Value/Revenue422.73
Enterprise Value/Gross Profit479.14
Enterprise Value/Ebitda-7.08
Forecast
1Y Price Target
$29.50Price Target Upside28.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.26
Revenue Forecast (FY)$6.40M
Bulls Say, Bears Say
Bulls Say
Durable Psoriasis EfficacySustained high skin-clearance rates in a Phase 3 extension support envudeucitinib’s potential clinical differentiation in oral psoriasis treatment. Durability and a favorable safety profile could improve its positioning if regulatory review and commercialization milestones are achieved.
Low Financial LeverageVery low debt relative to equity limits interest and refinancing pressure while the company advances its clinical programs. This provides more financial flexibility than a heavily debt-funded structure, although it does not remove the need to finance ongoing operating losses.
High Gross Margin PotentialThe high gross margin indicates that revenue, if commercial products scale, could carry substantial contribution after direct costs. That structure may support future operating leverage, although the benefit remains prospective because current research and operating expenses greatly exceed revenue.
Bears Say
Severe Cash BurnPersistent, deeply negative operating and free cash flow means Alumis cannot currently fund its operations from internally generated cash. Continued dependence on equity raises or other financing can dilute shareholders, constrain program choices, and increase funding risk before revenues scale.
Lupus Trial FailureMissing the main lupus endpoints weakens confidence that envudeucitinib can address the broader systemic lupus population and raises development uncertainty. The responder subgroup preserves a possible path forward, but additional trials and regulatory evidence may be required.
Large Losses And Declining RevenueMinimal and declining revenue currently provides little offset to very large operating expenses, leaving limited evidence of operating leverage. Deep losses could persist through late-stage development and delay self-sustaining profitability, increasing reliance on external capital.
Alumis Inc. News
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $4.28 and its highest was $31.35 in the past 12 months.
What is Alumis Inc.’s market cap?
Alumis Inc.’s market cap is $903.76M.
When is Alumis Inc.’s upcoming earnings report date?
Alumis Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 34 days.
How were Alumis Inc.’s earnings last quarter?
Alumis Inc. released its earnings results on Aug 19, 2026. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$0.767 by -$0.343.
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate is -0.75.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 129,435,240 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Alumis Inc. reported an EPS of -$1.11 in its last earnings report, missing expectations of -$0.767. Following the earnings report the stock price went down -3.577%.
Which hedge fund is a major shareholder of Alumis Inc.?
Currently, no hedge funds are holding shares in ALMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alumis Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.50 (28.09% Upside)
$29.50 (28.09% Upside)
Blogger Sentiment
Bullish
ALMS Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 619.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $9.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
57.33%
12-Months-Change
Fundamentals
Return on Equity
-102.97%
Trailing 12-Months
Asset Growth
-8.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
ALMS Stock 12 Month Forecast
Average Price Target
$29.50
▲(28.09% Upside)
Technical Analysis
Ownership Overview
43.93% Insiders
9.45% Mutual Funds
15.00% Other Institutional Investors
22.07% Public Companies and
Individual Investors